Temel İstatistikler
| CIK | 1348362 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lexaria Bioscience Corp
SEC Filings (Chronological Order)
Bu sayfa, başka bir yerde sunduğumuz mülkiyet başvuruları hariç, SEC Dosyalarının tam ve kronolojik bir listesini sunmaktadır.
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2026 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-39874 LEXAR |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2026 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 28, 2026 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp. |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2026 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 28, 2026 |
As filed with the Securities and Exchange Commission on January 28, 2026 As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. |
|
| January 14, 2026 |
Lexaria Bioscience Corp. 2,754,756 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-292469 PROSPECTUS Lexaria Bioscience Corp. 2,754,756 Shares of Common Stock This prospectus relates to the resale by the selling stockholders (the “Selling Stockholders”) named in this prospectus from time to time of up to 2,754,756 shares of our common stock, par value $0.001 per share (the “common stock”), consisting of (i) 2,661,600 shares o |
|
| January 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-39874 LEXAR |
|
| December 29, 2025 |
As filed with the Securities and Exchange Commission on December 29, 2025 As filed with the Securities and Exchange Commission on December 29, 2025 Registration No. |
|
| December 29, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Lexaria Bioscience Corp. |
|
| December 16, 2025 |
COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 14, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| December 16, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 16, 2025 |
Lexaria Bioscience Corp. 2,661,600 Shares of Common Stock Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 30, 2025) Registration No. |
|
| December 16, 2025 |
EXHIBIT 99.1 Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Kelowna, BC / ACCESS Newswire / December 15, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an a |
|
| December 16, 2025 |
EXHIBIT 99.2 Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Kelowna, BC / ACCESS Newswire / December 16, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering pri |
|
| December 16, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 14, 2025, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| December 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| December 9, 2025 |
PROSPECTUS Lexaria Bioscience Corp. 2,760,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-290862 PROSPECTUS Lexaria Bioscience Corp. 2,760,000 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 2,760,000 shares of our common stock, par value $0.001 per share (the “common stock”), issuable upon the exercise of 2,666,667 outstanding warrants to p |
|
| December 5, 2025 |
As filed with the Securities and Exchange Commission on December 5, 2025 As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. |
|
| December 5, 2025 |
As filed with the Securities and Exchange Commission on December 5, 2025 As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. |
|
| December 5, 2025 |
December 5, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| November 28, 2025 |
430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC EXHIBIT 10.11 Execution Version August 12, 2025 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher: This letter agreement (this “Agreement”), effective as of as of the date hereof, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co. |
|
| November 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 001-39874 Lexaria Bio |
|
| October 14, 2025 |
As filed with the Securities and Exchange Commission on October 14, 2025 As filed with the Securities and Exchange Commission on October 14, 2025 Registration No. |
|
| October 14, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Lexaria Bioscience Corp. |
|
| October 1, 2025 |
X0708 D LIVE 0001348362 Lexaria Bioscience Corp. 100 - 740 MCCURDY ROAD KELOWNA A1 BRITISH COLUMBIA, CANADA V1X 2P7 250-765-6424 NEVADA LEXARIA CORP. Lexaria Corp. Corporation true Christopher Bunka 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director John Docherty 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Executive Officer Director Richard Christoph |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commissio |
|
| September 29, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 26, 2025, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| September 29, 2025 |
EXHIBIT 99.1 Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Kelowna, BC / ACCESS Newswire / September 26, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an |
|
| September 29, 2025 |
Lexaria Bioscience Corp. 2,666,667 Shares of Common Stock Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated January 30, 2025) Registration No. |
|
| September 29, 2025 |
EXHIBIT 99.2 Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Kelowna, British Columbia - September 29, 2025 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced |
|
| September 29, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 29, 2025 |
COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commissi |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-39874 LEXARIA BI |
|
| July 14, 2025 |
Change Order to Project Agreement effective May 14, 2025 with Novotech (Australia) Pty Limited EXHIBIT 10.2 Change Order No. 1 Date: as per the last signature date of the Parties Parties 1. Novotech (Australia) Pty Limited ACN 071 874 881 of Level 19, 66 Goulburn Street, Sydney NSW 2000, Australia (Novotech) 2. Lexaria (AU) Pty Ltd of C/- Suite 1, Level 3, 62 Lygon Street, Carlton, Victoria, 3053, Australia (Sponsor) Background A On December 2, 2024, Novotech and Sponsor entered into a Proj |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| April 28, 2025 |
Lexaria Announces $2 Million Registered Direct Offering of Common Stock EXHIBIT 99.1 Lexaria Announces $2 Million Registered Direct Offering of Common Stock Kelowna, British Columbia – April 25, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2,000,000 |
|
| April 28, 2025 |
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock EXHIBIT 99.2 Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock Kelowna, British Columbia – April 28, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering with a single institutional investor for the p |
|
| April 28, 2025 |
EXHIBIT 1.2 Execution Version April 10, 2025 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher: Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of February 24, 2025, by and between Lexaria Bioscience Corp. (the “Company”) and H.C. Wai |
|
| April 28, 2025 |
Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| April 28, 2025 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 28, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-284407 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2025) Lexaria Bioscience Corp. 1,925,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 75,000 Shares of Common Stock We are offering 1,925,000 shares of our common stock, par value $0.001 per share, and pre-funded warrants to purchase up to 75,000 shares of our common |
|
| April 28, 2025 |
EXHIBIT 1.1 Execution Version February 24, 2025 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher: This letter agreement (this “Agreement”), effective as of as of the date hereof, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co. |
|
| April 28, 2025 |
Form of Placement Agent Warrant EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-39874 LEXAR |
|
| April 14, 2025 |
Form of Director Services Agreement EXHIBIT 10.3 Board of Directors Services Agreement (the “Agreement”) Effective this xx day of xx, 20xx. BETWEEN: LEXARIA BIOSCIENCE CORP. 100 – 740 McCurdy Road Kelowna, BC V1X 2P7 (the “Company”) AND: [name] [address] [city & state/province] [postal or zip code] (the “Director”) WHEREAS, the Company desires to retain the services of Director for the benefit of the Company and its stockholders; AN |
|
| February 5, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| February 5, 2025 |
Up to $5,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284407 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2025) Up to $5,000,000 of Common Stock We previously entered into a Capital on DemandTM Sales Agreement, dated August 21, 2024, as amended on February 5, 2025 (collectively, the “Sales Agreement”), with JonesTrading Institutional Services LLC, or Jones, relating to shares of our comm |
|
| February 5, 2025 |
EXHIBIT 10.1 February 5, 2025 Lexaria Bioscience Corp. 100 - 740 McCurdy Road, Kelowna, BC, Canada V1X 2P7 Re: Amendment No. 1 to Capital on Demand™ Sales Agreement Ladies and Gentlemen: Reference is made to the Capital on Demand™ Sales Agreement, dated as of August 21, 2024 (the “Sales Agreement”), between Lexaria Bioscience Corp (the “Company”) and JonesTrading Institutional Services LLC (“Jones |
|
| January 28, 2025 |
January 28, 2025 Richard Christopher Chief Executive Officer Lexaria Bioscience Corp. |
|
| January 28, 2025 |
January 28, 2025 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| January 22, 2025 |
As filed with the Securities and Exchange Commission on January 22, 2025 Registration Statement No. |
|
| January 22, 2025 |
Filing Fee Table (filed herewith) EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lexaria Bioscience Corp. |
|
| January 15, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
Executive Employment Agreement dated December 31, 2024 with John Docherty EXHIBIT 10.5 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 31st day of December, 2024. BETWEEN: Kelowna Management Services Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“KMSC”) AND: John Docherty, residing at: [xx]1 (the “Executive”) WHEREAS KMSC serves as the Canadian corporation which operates and manages the rea |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-39874 LEXAR |
|
| January 10, 2025 |
Project Agreement effective December 2, 2024 with Novotech (Australia) Pty Limited EXHIBIT 10.4 Project Agreement No. 01 Date: as per last signature date Parties 1. Novotech (Australia) Pty Limited ACN 071 874 881 of Level 19, 66 Goulburn Street, Sydney NSW 2000, Australia (Novotech) 2. Lexaria (AU) Pty Ltd ACN 679 491 920 C/- Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053, Australia (Sponsor) Background A On August 28, 2024, Novotech and Sponsor entered into a Master |
|
| January 6, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp. |
|
| January 6, 2025 |
As filed with the Securities and Exchange Commission on January 6, 2025 As filed with the Securities and Exchange Commission on January 6, 2025 Registration No. |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2024 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| December 16, 2024 |
As filed with the Securities and Exchange Commission on December 16, 2024 As filed with the Securities and Exchange Commission on December 16, 2024 Registration No. |
|
| December 5, 2024 |
PROSPECTUS 4,551,019 Shares of Common Stock underlying certain Common Warrants Filed pursuant to Rule 424(b)(3) Registration No.333-283484 PROSPECTUS 4,551,019 Shares of Common Stock underlying certain Common Warrants This prospectus relates to the resale from time to time by the selling stockholder identified herein of up to 4,551,019 shares of common stock, $0.001 par value (“Common Stock”), underlying those certain private placement warrants (the “Common Warrants”). We re |
|
| December 3, 2024 |
December 3, 2024 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| December 2, 2024 |
December 2, 2024 Richard Christopher Chief Executive Officer Lexaria Bioscience Corp. |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 26, 2024 |
EXHIBIT 10.10 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 1st day of October, 2024. BETWEEN: Lexaria Bioscience Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“LBC”) AND: Michael Shankman, having an address at: [xx]1 (the “Executive”) WHEREAS LBC serves as the Nasdaq listed parent company of the following subsidiar |
|
| November 26, 2024 |
As filed with the Securities and Exchange Commission on November 26, 2024. As filed with the Securities and Exchange Commission on November 26, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in Its Charter) Nevada 20-2000871 (State or Other Jurisdiction of Incorporation or Organization) (I.R. |
|
| November 26, 2024 |
EXHIBIT 21.1 Subsidiaries 100% owned by Lexaria Bioscience Corp. Poviva Corp. Lexaria Nutraceutical Corp. Lexaria Hemp Corp. Lexaria Pharmaceutical Corp. Lexaria (AU) Pty Ltd Kelowna Management Services Corp. Lexaria CanPharm Holding Corp. 100% owned by Lexaria CanPharm Holding Corp. Lexaria CanPharm ULC 83.333% owned by Lexaria Bioscience Corp. Lexaria Nicotine LLC |
|
| November 26, 2024 |
Clawback Policy, effective December 1, 2023 EXHIBIT 97.1 LEXARIA BIOSCIENCE CORP. CLAWBACK POLICY I. Purpose Lexaria Bioscience Corp. (the “Company”) is establishing this clawback policy (the “Policy”) in compliance with the Securities and Exchange Commission (“SEC”) and US stock exchange’s clawback rules and to align the interests of our current Executive Officers and those persons who were Executive Officers during any Look Back Period, w |
|
| November 26, 2024 |
Executive Employment Agreement dated August 31, 2024 with Richard Christopher EXHIBIT 10.9 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 31st day of August, 2024. BETWEEN: Lexaria Bioscience Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“LBC”) AND: Richard Christopher of [xx]1 (the “Executive”) WHEREAS LBC serves as the Nasdaq listed parent company of the following subsidiaries: Kelowna Manag |
|
| November 26, 2024 |
Filing Fee Table (filed herewith). EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Lexaria Bioscience Corp. |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-39874 Lexaria Bio |
|
| November 26, 2024 |
Insider Trading and Black-Out Period Policy, effective June 14, 2019 EXHIBIT 19.1 INSIDER TRADING AND BLACKOUT PERIOD POLICY Effective June 14, 2019 Updated March 15, 2024 LEXARIA BIOSCIENCE CORP. INSIDER TRADING AND BLACKOUT PERIOD POLICY 1.0 PURPOSE Lexaria Bioscience Corp. (the "Company") is a publicly traded company, domiciled in British Columbia and listed on United States exchanges/marketplaces. As such, trades in the Company's securities1 are subject to both |
|
| November 14, 2024 |
SC 13G/A 1 o10302414sc13ga3.htm AMENTMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3 )* LEXARIA BIOSCIENCE CORP. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 52886N406 (CUSIP Number) 2/22/2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 16, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| October 16, 2024 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 16, 2024 |
EXHIBIT 1.1 Execution Version September 4, 2024 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. 100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Chris Bunka, Chief Executive Officer Dear Mr. Bunka: This letter agreement (this “Agreement”), effective as of as of the date hereof, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwri |
|
| October 16, 2024 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 14, 2024, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 14, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| October 16, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 16, 2024 |
EXHIBIT 99.1 KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the- |
|
| October 16, 2024 |
Lexaria Bioscience Corp. 1,633,987 Shares of Common Stock Prospectus Supplement To Prospectus dated February 4, 2022 Filed pursuant to Rule 424(b)(5) Registration No. |
|
| October 16, 2024 |
EXHIBIT 99.2 Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia – October 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market u |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 1, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Lexaria Bioscience Corp. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 52886N (CUSIP Number) Robert B. Goldberg, Esq. 5555 Glenridge Connector, Suite 675 Atlanta, Georgia 30342 (404) 233-2800 (Name, Address and Telephone |
|
| September 5, 2024 |
Lexaria Releases Strategic Letter from the Outgoing CEO EXHIBIT 99.1 Lexaria Releases Strategic Letter from the Outgoing CEO Kelowna, British Columbia – September 5, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer (“CEO”) Chris Bunka as a strategic update to all stakeholders. CEO LETTER TO STAKEHOLDER |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 31, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| August 22, 2024 |
EXHIBIT 1.1 Lexaria Bioscience Corp Common Stock ($0.001 par value per share) Capital on Demand™ Sales Agreement August 21, 2024 JonesTrading Institutional Services LLC 325 Hudson Street., 6th Floor New York, NY 10013 Ladies and Gentlemen: Lexaria Bioscience Corp, a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agen |
|
| August 21, 2024 |
Up to $20,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262402 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022) Up to $20,000,000 of Common Stock We have entered into a Capital on DemandTM Sales Agreement, or Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, dated August 21, 2024, relating to shares of our common stock, par value $0.001 per share, or common |
|
| August 6, 2024 |
LEXX.W / Lexaria Bioscience Corp. - Equity Warrant / Boos Wayne W - 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Lexaria Bioscience Corp. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 52886N (CUSIP Number) Robert B. Goldberg, Esq. 5555 Glenridge Connector, Suite 675 Atlanta, Georgia 30342 (404)233-2800 (Name, Address and Telephone N |
|
| July 17, 2024 |
Positive Interim Body Weight Results from Lexaria’s Diabetes Animal Study EXHIBIT 99.1 Positive Interim Body Weight Results from Lexaria’s Diabetes Animal Study · DehydraTECH appears to work with a second GLP-1 drug – liraglutide · DehydraTECH appears to be working with semaglutide both with and without SNAC technology · DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 · Dosing in the final four study arms has now begun Kelowna, British Columbia |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 12, 2024 |
Form of Tail Warrant issued on April 30, 2024 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BI |
|
| June 11, 2024 |
Lexaria Bioscience Corp. 2,917,032 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279909 PROSPECTUS Lexaria Bioscience Corp. 2,917,032 Shares of Common Stock This prospectus relates to the resale from time to time by the selling stockholder named in this prospectus (the “Selling Stockholder”) of up to 2,917,032 shares of our common stock, par value $0.001 per share, issuable upon the exercise of an outstanding warrant issued |
|
| June 7, 2024 |
June 7, 2024 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| June 7, 2024 |
United States securities and exchange commission logo June 7, 2024 Christopher Bunka Chairman and Chief Executive Officer Lexaria Bioscience Corp. |
|
| June 3, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Lexaria Bioscience Corp. |
|
| June 3, 2024 |
As filed with the U.S. Securities and Exchange Commission on June 3, 2024 As filed with the U.S. Securities and Exchange Commission on June 3, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 2000 20-2000871 (State or other jurisdiction of incorporation or organization) (Primary Standard Indust |
|
| April 30, 2024 |
EXHIBIT 10.1 LEXARIA BIOSCIENCE CORP. April 30, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Lexaria Bioscience Corp. (the “Company”) is pleased to offer to you the opportunity to exercise the warrants to purchase shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), set forth on Exhibit |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 30, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Lexaria Bioscience Corp. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 52886N (CUSIP Number) Robert B. Goldberg, Esq. 5555 Glenridge Connector, Suite 675 Atlanta, Georgia 30342 (404)233-2800 (Name, Address and Telephone N |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 9, 2024 |
EXHIBIT 10.6 Amended and Restated INTELLECTUAL PROPERTY LICENSE AGREEMENT This Amended and Restated Intellectual Property License Agreement is made and entered as of the 15th day of March, 2024 (the “Effective Date”) by and between Lexaria Hemp Corp., a US corporation with offices at #100 – 740 McCurdy Road, Kelowna, British Columbia, Canada V1X 2P7, Canada (the “LICENSOR”), and Premier Anti-Aging |
|
| April 9, 2024 |
EXHIBIT 10.5 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 14th day of March, 2024. BETWEEN: Lexaria Bioscience Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“LBC”) AND: Nelson Cabatuan of [**]1 (the “Executive”) WHEREAS LBC serves as the Nasdaq listed parent company of the following subsidiaries: Kelowna Management |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXAR |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 20, 2024 |
PROSPECTUS Lexaria Bioscience Corp. 1,612,989 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-277863 PROSPECTUS Lexaria Bioscience Corp. 1,612,989 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 1,612,989 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued on February 16, 2024 pursuan |
|
| March 18, 2024 |
United States securities and exchange commission logo March 15, 2024 Christopher Bunka Chairman and Chief Executive Officer Lexaria Bioscience Corp. |
|
| March 18, 2024 |
March 18, 2024 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 12, 2024 |
EXHIBIT107 Calculation of Filing Fee Tables S-1 (Form Type) Lexaria Bioscience Corp. |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 29, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2024 |
EXHIBIT 1.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” Execution Version February 15, 2024 STRICTLY CONFIDENTIAL Reference is hereby made to that certain engagement letter, dated as of February 12, 2024 (the “Engagemen |
|
| February 16, 2024 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 16, 2024 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: February 16, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| February 16, 2024 |
EXHIBIT 99.2 Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia – February 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-marke |
|
| February 16, 2024 |
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EXHIBIT 99.1 Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia – February 15, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of commo |
|
| February 16, 2024 |
EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 16, 2024 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) To Prospectus dated February 4, 2022 Registration No. |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2024 |
EXHIBIT 1.1 Execution Version February 12, 2024 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. 100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Chris Bunka, Chief Executive Officer Dear Mr. Bunka: This letter agreement (this “Agreement”), effective as of February 12, 2023, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright” |
|
| February 16, 2024 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 14, 2024, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| February 14, 2024 |
LEXX / Lexaria Bioscience Corp. / Boos Wayne W - SCHEDULE 13D-A Activist Investment SC 13D/A 1 13dalexx.txt SCHEDULE 13D-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lexaria Bioscience Corp. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 52886N (CUSIP Number) Robert B. Goldberg, Esq. 5555 Glenridge Connector, Suite 675 Atlanta, Georgia 30342 (404) |
|
| February 14, 2024 |
SC 13G/A 1 lexx130240sc13ga2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* LEXARIA BIOSCIENCE CORP. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 52886N406 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2024 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 24, 2024 |
EXHIBIT 99.1 CEO LETTER TO STAKEHOLDERS According to the Wall Street Journal, near the end of 2023, there were 446 companies listed on the Nasdaq that were trading under $1 and risking being de-listed; compared to nearly nil in 2021. It was a tough year for microcap companies, which are often too early-stage to have profitable operations and withstand the harsh realities of the investment banking |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2024 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 24, 2024 |
As filed with the Securities and Exchange Commission on January 24, 2024 As filed with the Securities and Exchange Commission on January 24, 2024 Registration No. |
|
| January 18, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp. |
|
| January 18, 2024 |
As filed with the Securities and Exchange Commission on January 18, 2024 As filed with the Securities and Exchange Commission on January 18, 2024 Registration No. |
|
| January 18, 2024 |
EXHIBIT 4.1 LEXARIA BIOSCIENCE CORP. EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentive to Employees, Directors, and Consultants, and (c) to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Opt |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 Lexar |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| January 4, 2024 |
EXHIBIT 99.1 Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®: · Sustained higher levels of semaglutide in blood; · Better blood glucose control; · Faster achievement of peak drug delivery; and · Reduced side effects. Kelowna, British Columb |
|
| December 8, 2023 |
Lexaria Bioscience Corp. 1,618,330 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275810 PROSPECTUS Lexaria Bioscience Corp. 1,618,330 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus from time to time of up to 1,618,330 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued in October 2023 (the “Warrant |
|
| December 6, 2023 |
United States securities and exchange commission logo December 6, 2023 Christopher Bunka Chairman and Chief Executive Officer Lexaria Bioscience Corp. |
|
| December 6, 2023 |
December 6, 2023 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 30, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp. |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 Lexaria Bioscienc |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| October 16, 2023 |
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn EXHIBIT 99.1 Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn · Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded · Minimum ongoing payments, royalties and manufacturing revenues part of the agreement Kelowna, British Columbia – October 13, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the |
|
| October 12, 2023 |
EXHIBIT 99.1 Lexaria Granted Two New Patents in Canada · Lexaria now holds 37 granted patents world-wide · Potential application in treating nicotine addiction Kelowna, British Columbia – October 12, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has been granted two new patents by the Canadian |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 10, 2023 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commissio |
|
| October 3, 2023 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT September 28, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Lexaria Bioscience Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $1,569,780.10 of registered and unregistered securities of the Company, including, but |
|
| October 3, 2023 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 3, 2023 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| October 3, 2023 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2023, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| October 2, 2023 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) To Prospectus dated February 4, 2022 Registration No. |
|
| September 18, 2023 |
LEXX / Lexaria Bioscience Corp / Boos Wayne W - SCHEDULE 13D Activist Investment SC 13D 1 13dlexx.txt SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Lexaria Bioscience Corp. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 52886N (CUSIP Number) Robert B. Goldberg, Esq. 5555 Glenridge Connector, Suite 675 Atlanta, Georgia 30342 (404)233-28 |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 28, 2023 |
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study EXHIBIT 99.1 Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study Kelowna, British Columbia – July 28, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). The es |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| July 14, 2023 |
EXHIBIT 10.3 |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BI |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 001-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2023 |
EXHIBIT 10.2 PLACEMENT AGENCY AGREEMENT May 8, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Lexaria Bioscience Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,000,7000 of registered units (the “Units”) of the Company, each Unit consisting of either |
|
| May 10, 2023 |
Filed pursuant to Rule 424(b)(4) Registration No. 333-271096 PROSPECTUS 2,106,000 Units, Each Unit Consisting of One Share of Common Stock and One Common Warrant to Purchase One Share of Common Stock Common Stock Underlying the Common Warrants We are offering on a best-efforts basis 2,106,000 units, each unit consisting of one share of common stock and one common warrant to purchase one share of c |
|
| May 10, 2023 |
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering EXHIBIT 99.1 Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering KELOWNA, BC / ACCESSWIRE / MAY 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the pricing of its public offering of 2,106,000 units, with each unit consisting of one share of common stock and one warrant to p |
|
| May 5, 2023 |
May 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Lexaria Bioscience Corp. Registration Statement on Form S-1, as amended File No. 333-271096 Ladies and Gentlemen: As the placement agent of the proposed offering of Lexaria Bioscience Corp. (the “Company”), we hereby join the Company’s request for acceler |
|
| May 5, 2023 |
May 5, 2023 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| May 4, 2023 |
May 4, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Lexaria Bioscience Corp. |
|
| May 4, 2023 |
Lexaria Bioscience Corp. 100-740 McCurdy Road, Kelowna British Columbia, Canada, V1X 2P7 May 4, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Lexaria Bioscience Corp Registration Statement on Form S-1, as amended Initially filed on April 3, 2023, as amende |
|
| May 3, 2023 |
May 3, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Lexaria Bioscience Corp. Registration Statement on Form S-1, as amended File No. 333-271096 Ladies and Gentlemen: As the placement agent of the proposed offering of Lexaria Bioscience Corp. (the “Company”), we hereby join the Company’s request for acceler |
|
| May 3, 2023 |
May 3, 2023 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| April 28, 2023 |
EXHIBIT 10.8 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April , 2023, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| April 28, 2023 |
EXHIBIT 4.5 COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: April , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initi |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
Form of Placement Agent Agreement* EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT April , 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Lexaria Bioscience Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $[] of registered units (the “Units”) of the Company, each Unit consisting of either (a) one |
|
| April 28, 2023 |
EXHIBIT 10.9 LEXARIA BIOSCIENCE CORP. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Warrant Agent Warrant Agency Agreement Dated as of April , 2023 EXECUTION VERSION WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of April , 2023 (“Agreement”), between Lexaria Bioscience Corp., a corporation organized under the laws of the State of Nevada (the “Company”), and Compute |
|
| April 28, 2023 |
EXHIBIT 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: April , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXAR |
|
| April 7, 2023 |
United States securities and exchange commission logo April 7, 2023 Christopher Bunka Chief Executive Officer Lexaria Bioscience Corp. |
|
| April 3, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lexaria Bioscience Corp. |
|
| April 3, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| March 22, 2023 |
DEF 14A 1 lxrpdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 3, 2023 |
EXHIBIT 99.1 Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels Kelowna, British Columbia – March 2, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that its diabetes animal model study DIAB-A22-1 has completed and produced at least three |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 2, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 10, 2023 |
LEXX / Lexaria Bioscience Corp / Invenomic Capital Management LP - FORM 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1) Lexaria Bioscience Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 52886N406 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file numb |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 17, 2023 |
EXHIBIT 99.1 CEO LETTER TO STAKEHOLDERS As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people - are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control such as applied R&D designed to entice others to work with us commercially. Inflation rates running at 40-year highs have prompted inte |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIE |
|
| December 28, 2022 |
As filed with the Securities and Exchange Commission on December 28, 2022 POS AM 1 lxrpposam.htm POS AM As filed with the Securities and Exchange Commission on December 28, 2022 Registration No. 333-238915 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevad |
|
| December 21, 2022 |
As filed with the Securities and Exchange Commission on December 21, 2022 As filed with the Securities and Exchange Commission on December 21, 2022 Registration Nos. |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 LEXARIA BIOSCIENC |
|
| November 28, 2022 |
Letter of Davidson & Company LLP dated November 28, 2022 EX-16.1 2 lxrpex161.htm LETTER OF DAVIDSON EXHIBIT 16.1 November 28, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549, USA Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated November 25, 2022 of Lexaria Bioscience Corp. (the “Company”) and are in agreement with the statements contained in paragraphs 2 and 3 on Page 2 therein. We have no basis to agree or |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 25, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| October 28, 2022 |
Lexaria’s Human Clinical Hypertension Study a Success EXHIBIT 99.1 Lexaria’s Human Clinical Hypertension Study a Success HYPER-H21-4 using DehydraTECH-CBD evidenced: · Exceptional safety and tolerability · Statistically significant lowering of 24-hour ambulatory blood pressure (“BP”) · BP lowered for the entire 5-week study duration · BP lowered both for patients currently taking other antihypertensive drugs as well as patients not taking any other a |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2022 |
EX-1.1 2 lxrpex11.htm EQUITY DISTRIBUTION AGREEMENT EXHIBIT 1.1 Lexaria Bioscience Corp. Up to $5,925,000 of Shares of Common Stock Equity Distribution Agreement August 12, 2022 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Lexaria Bioscience Corp., a Nevada corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), a |
|
| August 12, 2022 |
Financial Statements and Exhibits, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2022 |
Lexaria Bioscience Corp. Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-262402 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 4, 2022) Lexaria Bioscience Corp. $5,925,000 Common Stock We have entered into an equity distribution agreement (the ?Sales Agreement?) with Maxim Group LLC (?Maxim? or the ?Distribution Agent?), dated August 12, 2022, relating to the sale of shares of our common stock offered |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIENCE C |
|
| July 14, 2022 |
EXHIBIT 10.3 CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN EXCLUDED WHERE ITS DISCLOSURE WOULD BE COMPETITIVELY HARMFUL. INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (this ?Agreement?) dated as of May 20, 2022 (the ?Effective Date?) is made by and between Lexaria Hemp Corp., a US corporation with offices at #100 ? 740 McCurdy Road, Kelowna, British Columbia, |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| June 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File |
|
| April 20, 2022 |
Zacks Investment Research Report Update EXHIBIT 99.1 |
|
| April 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIE |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 LEXARIA BIOSCIENCE CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 52886N406 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 14, 2022 |
LEXX / Lexaria Bioscience Corp / Invenomic Capital Management LP - LEXARIA - 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.) Lexaria Bioscience Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 52886N406 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 2, 2022 |
Zacks Investment Research Report Update EXHIBIT 99.1 |
|
| February 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| February 1, 2022 |
United States securities and exchange commission logo February 1, 2022 Christopher Bunka Chief Executive Officer Lexaria Bioscience Corp. |
|
| February 1, 2022 |
Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, British Columbia V1X 2P7 CORRESP 1 filename1.htm Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, British Columbia V1X 2P7 1-250-765-6424 February 1, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Mr. Gary Guttenberg Re: Lexaria Bioscience Corp. Registration Statement on Form S-3 Filed January 28, 2022 File No. 333-262402 Ladies and Gent |
|
| January 28, 2022 |
As filed with the Securities and Exchange Commission on January 28, 2022 Registration Statement No. |
|
| January 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| January 27, 2022 |
Lexaria Provides Annual Letter From the CEO EXHIBIT 99.1 Lexaria Provides Annual Letter From the CEO Kelowna, British Columbia ? January 27, 2022 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms, is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders. Dear Shareholders, Will anyone ever forget 2021? |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIE |
|
| January 14, 2022 |
EXHIBIT 10.2 INDEPENDENT CONTRACTOR AGREEMENT THIS CONTRACT IS MADE AS OF DECEMBER 31, 2021 BETWEEN: LEXARIA BIOSCIENCE CORP. of 100 ? 740 McCurdy Road, Kelowna, BC V1X 2P7 (hereinafter referred to as the ?Company?) OF THE FIRST PART - and - C.A.B. FINANCIAL SERVICES LTD. of [xx]1 (hereinafter referred to as the ?Contractor?) OF THE SECOND PART WHEREAS Company wishes to contract for the services o |
|
| January 14, 2022 |
EX-10.1 2 lxrpex101.htm EX-10.1 EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 31st day of December, 2021. BETWEEN: Kelowna Management Services Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“KMSC”) AND: John Docherty, residing at: [xx]i1 (the “Executive”) WHEREAS KMSC serves as the Canadian corporation w |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| December 28, 2021 |
1,659,448 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants 424B3 1 lxrp424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-250326 and 333-252031 PROSPECTUS 1,659,448 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the issuance of up to 1,659,448 shares of our common stock, par value $0.001 per share, upon the exercise of the following warrants: (1) warrants to purchase 1,575,951 shares of |
|
| December 28, 2021 |
PROSPECTUS 434,085 SHARES OF COMMON STOCK 424B3 1 lxrp424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-238915 PROSPECTUS 434,085 SHARES OF COMMON STOCK This prospectus relates to the offering and resale by the selling stockholders identified herein of up to 434,085 shares of common stock issued or issuable to such selling stockholders, including 352,763 shares of common stock issuable upon the exercise of outstanding |
|
| December 20, 2021 |
Zacks Investment Research Report Update EXHIBIT 99.1 |
|
| December 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
|
| December 17, 2021 |
As filed with the Securities and Exchange Commission on December 17 2021 As filed with the Securities and Exchange Commission on December 17 2021 Registration Number 333-250326 and 333-252031 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post- Effective Amendment No. |
|
| December 17, 2021 |
As filed with the Securities and Exchange Commission on December 17, 2021 As filed with the Securities and Exchange Commission on December 17, 2021 Registration No. |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission |
